The Supply of Investigational Medicinal Product and Management of Study Materials for Decentralized Participants—Insights from the Trials@Home <scp>RADIAL</scp> Proof‐of‐Concept Trial

Decentralized clinical trials (DCTs), which move trial activities to participants' homes or direct surroundings, offer potential advantages over conventional site-based trials through reduced participant burden and improved accessibility. The direct-to-participant (DtP) delivery of investigational medicinal products (IMPs) and other study materials and collection of biological samples requires careful planning and execution to ensure participant safety and data integrity. Here, we report operational experiences from the RADIAL proof-of-concept trial, a three-arm parallel-group study conducted across six European countries comparing conventional, hybrid, and fully decentralized approaches in type 2 diabetes patients. The study implemented two DtP IMP models: clinical trial site-to-participant and central pharmacy-to-participant delivery, with comprehensive logistics tracking and temperature monitoring. In RADIAL, 68 DtP IMP shipments were executed with a 94% successful delivery rate. Four shipments (6%) failed due to participant unavailability, temperature excursions, defective monitoring equipment, or courier loss. The central pharmacy model demonstrated inventory savings compared with conventional site-based distribution. Biological sample collection for HbA1c assessment was done through drop-off, which proved more challenging in the remote arm. Key challenges related to DCT logistics as experienced in RADIAL included unclear importer/exporter responsibilities, regulatory divergence across countries, participant material management, and sample drop-off reliability. DtP IMP delivery and biological sample collection are feasible in European DCTs but require enhanced planning, clear vendor responsibilities, and robust contingency procedures. Success depends on appropriate participant training, reliable courier services, temperature control systems, and accessible biological sample collection methods.

Authors

Institutions

Publication Details

Journal
Clinical Pharmacology & Therapeutics
Published
2025-09-24
DOI
https://doi.org/10.1002/cpt.70072
Citations
1
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
3.13

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Supply of Investigational Medicinal Product and Management of Study Materials for Decentralized Participants—Insights from the Trials@Home RADIAL Proof‐of‐Concept Trial

Bart Lagerwaard, Mira G. P. Zuidgeest, Amos J. de Jong, Megan Heath et al.
1 citations
Clinical Pharmacology & Therapeutics
Health Systems, Economic Evaluations, Quality of Life
3.13
article

The Supply of Investigational Medicinal Product and Management of Study Materials for Decentralized Participants—Insights from the Trials@Home RADIAL Proof‐of‐Concept Trial

Bart Lagerwaard, Mira G. P. Zuidgeest, Amos J. de Jong, Megan Heath, Chao Jin, Danny R. van Weelij, Shaun Magorrian‐Spence, Lucas Pagnier, Yvonne van Rijswick, Volker Haufe
article en
1 citations

Abstract

Decentralized clinical trials (DCTs), which move trial activities to participants' homes or direct surroundings, offer potential advantages over conventional site-based trials through reduced participant burden and improved accessibility. The direct-to-participant (DtP) delivery of investigational medicinal products (IMPs) and other study materials and collection of biological samples requires careful planning and execution to ensure participant safety and data integrity. Here, we report operational experiences from the RADIAL proof-of-concept trial, a three-arm parallel-group study conducted across six European countries comparing conventional, hybrid, and fully decentralized approaches in type 2 diabetes patients. The study implemented two DtP IMP models: clinical trial site-to-participant and central pharmacy-to-participant delivery, with comprehensive logistics tracking and temperature monitoring. In RADIAL, 68 DtP IMP shipments were executed with a 94% successful delivery rate. Four shipments (6%) failed due to participant unavailability, temperature excursions, defective monitoring equipment, or courier loss. The central pharmacy model demonstrated inventory savings compared with conventional site-based distribution. Biological sample collection for HbA1c assessment was done through drop-off, which proved more challenging in the remote arm. Key challenges related to DCT logistics as experienced in RADIAL included unclear importer/exporter responsibilities, regulatory divergence across countries, participant material management, and sample drop-off reliability. DtP IMP delivery and biological sample collection are feasible in European DCTs but require enhanced planning, clear vendor responsibilities, and robust contingency procedures. Success depends on appropriate participant training, reliable courier services, temperature control systems, and accessible biological sample collection methods.

Clinical Pharmacology & TherapeuticsVol. 118(5)
Sanofi (France) (FR), University Medical Center Utrecht (NL), Fresenius Kabi (Netherlands) (NL), Sanofi (China) (CN), Sanofi (Germany) (DE), Yulius (NL), Sanofi (United Kingdom) (GB)
Sanofi, European Federation of Pharmaceutical Industries and Associations, European Commission
Openalex Percentile: Top 6%
Health Systems, Economic Evaluations, Quality of Life
3.13
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.